PETALING JAYA: Integrated global healthcare provider IHH Healthcare Bhd’s long-term prospects remains bright amid external headwinds.
RHB Research said it remains positive on IHH’s long-term prospect as it likes the group’s solid execution strategy, reputable regional footprint across key regions driven by its strong brand awareness, inelastic demand nature towards healthcare services and focus on affluent clientele.
Furthermore, the research house said in its recent visit to Istanbul, it was delighted to know IHH’s 90%-owned Turkiye-based subsidiary Acibadem Healthcare Group plans to gradually incorporate its in-house proprietary system (C+) to Singapore and Malaysia (completed in Pantai and Gleneagles hospitals, except Prince Court), which could eventually lead to better operating efficiency and improve customer experience.
However, it noted that key risks for IHH include external economic headwinds such as hyperinflationary environment and the risk of the economy slowing down post-interest rate hike.
Nevertheless, the group’s effort in diversifying towards non-try exposure as well as timely price adjustments, offers hope.
Acibadem is one of the leading private healthcare service providers of high-quality diagnostic and treatment services in Turkiye.
Since its founding in 1991, the group has grown to become Turkiye’s flagship healthcare provider with 24 hospitals and 14 outpatient clinics across five countries – Turkiye, Macedonia, Serbia, Bulgaria, and the Netherlands.
Today, Acibadem prides itself as the centre of excellence, not only in the space of healthcare services, but also academically (following the opening of Acibadem University in 2007).
Five out of Acibadem’s 24 hospitals are Joint Commission International-certified for adapting the international gold standard for quality and patient safety.
Acibadem continues to eye merger and acquisition opportunities as it plans to add a total of 580 beds (380 in Turkiye and 200 in Europe) over the next three years.